Guerbet Future Growth

Future criteria checks 4/6

Guerbet is forecast to grow earnings and revenue by 23.6% and 7% per annum respectively. EPS is expected to grow by 23.4% per annum. Return on equity is forecast to be 10.2% in 3 years.

Key information

23.6%

Earnings growth rate

23.4%

EPS growth rate

Medical Equipment earnings growth	13.8%
Revenue growth rate	7.0%
Future return on equity	10.2%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

Is Guerbet (EPA:GBT) Using Too Much Debt?

Apr 27

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

Feb 29

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Mar 28

Is Guerbet (EPA:GBT) A Risky Investment?

Oct 25

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Sep 23

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

May 27

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

May 04

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Apr 05

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 19

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

Mar 01

When Should You Buy Guerbet SA (EPA:GBT)?

Feb 10

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 28

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Jan 13

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

Dec 23

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Dec 11

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

Nov 27

Earnings and Revenue Growth Forecasts

ENXTPA:GBT - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	984	48	57	136	4
12/31/2025	918	40	46	121	5
12/31/2024	858	29	25	97	4
12/31/2023	796	24	-26	27	N/A
9/30/2023	785	-9	-38	15	N/A
6/30/2023	775	-42	-51	3	N/A
3/31/2023	772	-42	-35	17	N/A
12/31/2022	769	-41	-19	30	N/A
9/30/2022	757	-14	-1	49	N/A
6/30/2022	746	13	17	67	N/A
3/31/2022	741	23	43	92	N/A
12/31/2021	736	33	68	116	N/A
9/30/2021	724	33	59	109	N/A
6/30/2021	712	33	51	103	N/A
3/31/2021	715	26	56	112	N/A
12/31/2020	717	18	62	120	N/A
9/30/2020	751	22	86	142	N/A
6/30/2020	785	26	110	163	N/A
3/31/2020	802	32	91	147	N/A
12/31/2019	819	37	72	131	N/A
9/30/2019	813	40	52	110	N/A
6/30/2019	807	43	32	88	N/A
3/31/2019	801	45	33	83	N/A
12/31/2018	795	47	33	77	N/A
9/30/2018	793	46	29	68	N/A
6/30/2018	790	46	24	59	N/A
3/31/2018	800	46	19	58	N/A
12/31/2017	809	46	14	56	N/A
9/30/2017	807	43	N/A	46	N/A
6/30/2017	805	40	N/A	35	N/A
3/31/2017	791	34	N/A	37	N/A
12/31/2016	776	29	N/A	39	N/A
9/30/2016	709	30	N/A	46	N/A
6/30/2016	642	31	N/A	54	N/A
3/31/2016	566	35	N/A	60	N/A
12/31/2015	490	39	N/A	66	N/A
9/30/2015	462	37	N/A	67	N/A
6/30/2015	435	35	N/A	69	N/A
3/31/2015	422	30	N/A	64	N/A
12/31/2014	410	26	N/A	60	N/A
9/30/2014	405	24	N/A	59	N/A
6/30/2014	400	23	N/A	57	N/A
3/31/2014	395	22	N/A	58	N/A
12/31/2013	391	20	N/A	59	N/A
9/30/2013	394	19	N/A	54	N/A
6/30/2013	398	17	N/A	49	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GBT's forecast earnings growth (23.6% per year) is above the savings rate (1.1%).

Earnings vs Market: GBT's earnings (23.6% per year) are forecast to grow faster than the French market (11% per year).

High Growth Earnings: GBT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GBT's revenue (7% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: GBT's revenue (7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GBT's Return on Equity is forecast to be low in 3 years time (10.2%).

Guerbet Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Guerbet SA Provides Earnings Guidance for the Year 2024

Price target increased by 22% to €36.38

Price target increased by 8.4% to €20.68

Price target decreased by 14% to €20.65

Consensus EPS estimates fall by 26%

Price target decreased to €23.94

Recent updates

Is Guerbet (EPA:GBT) Using Too Much Debt?

Guerbet SA Provides Earnings Guidance for the Year 2024

Dividend of €0.50 announced

Price target increased by 22% to €36.38

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

New minor risk - Share price stability

Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture

Price target increased by 8.4% to €20.68

Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch

Guerbet SA, Annual General Meeting, May 24, 2024

First half 2023 earnings released: EPS: €0.16 (vs €0.26 in 1H 2022)

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Guerbet Announces Management Appointments

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection

Full year 2022 earnings released: €3.25 loss per share (vs €2.59 profit in FY 2021)

Price target decreased by 14% to €20.65

Consensus EPS estimates fall by 26%

Guerbet Releases First Production Batch of Elucirem (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging

Guerbet SA, Annual General Meeting, May 26, 2023

Price target decreased to €23.94

Consensus forecasts updated

Price target decreased to €26.82

First half 2022 earnings released: EPS: €0.26 (vs €1.86 in 1H 2021)

Price target decreased to €30.90

Consensus forecasts updated

Price target decreased to €32.80

Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem (Gadopiclenol)

Price target decreased to €31.55

Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price

Guerbet SA Confirms Revenue Guidance for the Year of 2022

Price target decreased to €36.18

Upcoming dividend of €0.85 per share

Guerbet Sa Provides Revenue Guidance for 2022

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet Recently Submitted New Drug Application to the U.S. Food and Drug Administration

Full year 2021 earnings: Revenues in line with analyst expectations

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Is Guerbet (EPA:GBT) A Risky Investment?

First half 2021 earnings released

Guerbet Provides Group Earnings Guidance for the Year 2021

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Price target increased to €33.75

Consensus forecasts updated

Upcoming dividend of €0.70 per share

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Full year 2020 earnings released

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

New 90-day low: €29.85

Analysts update estimates

Guerbet SA to Report Fiscal Year 2020 Results on Mar 24, 2021

When Should You Buy Guerbet SA (EPA:GBT)?

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Guerbet SA, Annual General Meeting, May 28, 2021

New 90-day high: €35.65

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

New 90-day high: €33.10

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Guerbet SA Receives Us Food and Drug Administration Approval for the Commercial Sale of the Optiray Imaging Bulk Package (IBP)

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

New 90-day high: €30.00

Analysts lower EPS estimates to €1.64

Price target lowered to €31.00

First half earnings released

Analysts lower EPS estimates to €1.98

Price target lowered to €31.17